Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer

Introduction: Immunochemotherapy using PD-1/PD-L1 antibodies in combination with chemotherapeutic agents has become a mainstream treatment for cancer patients, but it remains unclear which drug combinations would produce best therapeutic outcome. Objectives: The purpose of this study was to investig...

Full description

Bibliographic Details
Main Authors: Christophe Glorieux, Xiaojun Xia, Xin You, Zining Wang, Yi Han, Jing Yang, Gauthier Noppe, Christophe de Meester, Jianhua Ling, Annie Robert, Hui Zhang, Sheng-Ping Li, Huamin Wang, Paul J. Chiao, Li Zhang, Xiaobing Li, Peng Huang
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Journal of Advanced Research
Subjects:
K-ras
Cisplatin
Gemcitabine
PD-1/PD-L1
Immunochemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2090123221002599

Internet

http://www.sciencedirect.com/science/article/pii/S2090123221002599

Similar Items